IN THE CLAIMS

1-37. (Canceled)

38. (Currently amended) A method of inhibiting production of IgE in a human subject with an IgE-mediated allergic disorder comprising parenterally administering an IgE production inhibiting amount of an anti-human CD23 monoclonal antibody comprising a human gamma-1 constant region;

which antibody ~~competes for binding to CD23 with an antibody comprising~~ comprises the complementarity-determining regions CDR1, CDR2, and CDR3 of the light and heavy chains of antibody 6G5 or of antibody 5E8; wherein

CDR1, CDR2, and CDR3 of the light chain of antibody 6G5 are the polypeptides encoded by nucleotides 124-165, 211-231, and 328-357, respectively, of SEQ ID NO. 1;

CDR1, CDR2, and CDR3 of the heavy chain of antibody 6G5 are the polypeptides encoded by nucleotides 148-165, 208-258, and 355-390, respectively, of SEQ ID NO. 3;

CDR1, CDR2, and CDR3 of the light chain of antibody 5E8 are the polypeptides encoded by nucleotides 136-168, 214-234, and 331-357, respectively, of SEQ ID NO. 5; and

CDR1, CDR2, and CDR3 of the heavy chain of antibody 5E8 are the polypeptides encoded by nucleotides 148-168, 211-261, and 358-378, respectively, of SEQ ID NO. 7.

39. (Canceled) The method of Claim 38, wherein the anti-human CD23 monoclonal antibody that is administered comprises the complementarity-determining regions CDR1, CDR2, and CDR3 of the light and heavy chains of an antigen binding portion of a primate anti-human CD23 antibody.

40. (Canceled) The method of Claim 38, wherein the anti-human CD23 monoclonal antibody that is administered is a human gamma-1 monoclonal antibody.

41. (Canceled) The method of Claim 38, wherein the anti-human CD23 monoclonal antibody that is administered comprises an antigen-binding portion of a rodent anti-human CD23 antibody.

42. (Previously presented) The method of Claim 38, wherein the anti-human CD23 monoclonal antibody that is administered is a humanized antibody.

43. (Previously presented) The method of Claim 38, wherein the anti-human CD23 monoclonal antibody that is administered inhibits production of IgE *in vitro*.

44. (Previously presented) The method of Claim 43, wherein the anti-human CD23 monoclonal antibody that is administered inhibits IL-4 induced production of IgE by B cells *in vitro*.

45. (Previously presented) The method of Claim 38, wherein the anti-human CD23 monoclonal antibody that is administered inhibits IL-4 induced production of IgE *in vivo*.

46. (Canceled) The method of Claim 39, wherein the anti-human CD23 monoclonal antibody that is administered comprises the complementarity-determining regions CDR1, CDR2, and CDR3 of the light and heavy chains of antibody 6G5 or of antibody 5E8; wherein

CDR1, CDR2, and CDR3 of the light chain of antibody 6G5 are the polypeptides encoded by nucleotides 124-165, 211-231, and 328-357, respectively, of SEQ ID NO. 1;

CDR1, CDR2, and CDR3 of the heavy chain of antibody 6G5 are the polypeptides encoded by nucleotides 148-165, 208-258, and 355-390, respectively, of SEQ ID NO. 3;

CDR1, CDR2, and CDR3 of the light chain of antibody 5E8 are the polypeptides encoded by nucleotides 136-168, 214-234, and 331-357, respectively, of SEQ ID NO. 5; and

CDR1, CDR2, and CDR3 of the heavy chain of antibody 5E8 are the polypeptides encoded by nucleotides 148-168, 211-261, and 358-378, respectively, of SEQ ID NO. 7.

47. (Currently amended) A method of treating an IgE mediated allergic disorder in a human subject comprising parenterally administering a therapeutically effective amount of an anti-human CD23 monoclonal antibody comprising a human gamma-1 constant region; which antibody ~~competes for binding to CD23 with an antibody comprising~~ comprises the complementarity-determining regions CDR1, CDR2, and CDR3 of the light and heavy chains of antibody 6G5 or of antibody 5E8; wherein

CDR1, CDR2, and CDR3 of the light chain of antibody 6G5 are the polypeptides encoded by nucleotides 124-165, 211-231, and 328-357, respectively, of SEQ ID NO. 1;

CDR1, CDR2, and CDR3 of the heavy chain of antibody 6G5 are the polypeptides encoded by nucleotides 148-165, 208-258, and 355-390, respectively, of SEQ ID NO. 3;

CDR1, CDR2, and CDR3 of the light chain of antibody 5E8 are the polypeptides encoded by nucleotides 136-168, 214-234, and 331-357, respectively, of SEQ ID NO. 5; and

CDR1, CDR2, and CDR3 of the heavy chain of antibody 5E8 are the polypeptides encoded by nucleotides 148-168, 211-261, and 358-378, respectively, of SEQ ID NO. 7.

48. (Canceled) The method of claim 47, wherein the anti-human CD23 monoclonal antibody that is administered is selected from the group consisting of a human gamma-1 antibody, an antibody comprising an antigen-binding portion of a rodent anti-human CD23 antibody, and an antibody comprising an antigen-binding portion of a primate anti-human CD23 antibody.

49. (Canceled) The method of claim 48, wherein the anti-human CD23 monoclonal antibody that is administered comprises the complementarity-determining regions CDR1, CDR2, and CDR3 of the light and heavy chains of antibody 6G5 or of antibody 5E8; wherein

CDR1, CDR2, and CDR3 of the light chain of antibody 6G5 are the polypeptides encoded by nucleotides 124-165, 211-231, and 328-357, respectively, of SEQ ID NO. 1;

CDR1, CDR2, and CDR3 of the heavy chain of antibody 6G5 are the polypeptides encoded by nucleotides 148-165, 208-258, and 355-390, respectively, of SEQ ID NO. 3;

CDR1, CDR2, and CDR3 of the light chain of antibody 5E8 are the polypeptides encoded by nucleotides 136-168, 214-234, and 331-357, respectively, of SEQ ID NO. 5; and

CDR1, CDR2, and CDR3 of the heavy chain of antibody 5E8 are the polypeptides encoded by nucleotides 148-168, 211-261, and 358-378, respectively, of SEQ ID NO. 7.

50. (Currently amended) The method of ~~any one of claims 47, 48 or 49~~ claim 47, wherein said allergic disorder is selected from the group consisting of allergic rhinitis, allergic contact dermatitis, anaphylactic reactions, asthma, and bronchitis.

51. (Currently amended) The method of ~~any one of claims 47, 48 or 49~~ claim 47, wherein parenteral administration includes subcutaneous, intravenous, intramuscular, rectal, vaginal and intraperitoneal administration.

52. (Canceled)

53. (Previously presented) The method of claim 51, wherein the antibody is administered by subcutaneous administration.

54. (Previously presented) The method of claim 51, wherein the antibody is lyophilized for storage and reconstituted prior to administration.

55. (Currently amended) The method of Claim ~~39~~ 38, wherein the anti-human CD23 monoclonal antibody that is administered comprises the variable regions of the light and heavy chains of antibody 6G5 having the sequences shown as amino acids 1-111 of SEQ ID NO: 2 and amino acids 1-122 of SEQ ID NO: 4, respectively.

56. (Currently amended) The method of claim ~~39~~ 38, wherein the anti-human CD23 monoclonal antibody that is administered comprises the variable regions of the light and heavy chains of antibody 5E8 having the amino acid sequences shown as amino acids 1-107 of SEQ ID NO: 6 and amino acids 1-118 SEQ ID NO: 8, respectively.

57. (Previously presented) The method of claim 38, wherein said allergic disorder is selected from the group consisting of allergic rhinitis, allergic contact dermatitis, anaphylactic reactions, asthma, and bronchitis.

58. (Previously presented) The method of claim 38, wherein parenteral administration includes subcutaneous, intramuscular, intravenous, rectal, vaginal and intraperitoneal administration.

59. (Previously presented) The method of claim 58, wherein the antibody is administered by subcutaneous administration.

60. (Canceled) The method of Claim 49, wherein the anti-human CD23 monoclonal antibody that is administered comprises the variable regions of the light and heavy chains of antibody 6G5 having the sequences shown as amino acids 1-111 of SEQ ID NO: 2 and amino acids 1-122 of SEQ ID NO: 4, respectively.

61. (Canceled) The method of claim 49, wherein the anti-human CD23 monoclonal antibody that is administered comprises the variable regions of the light and heavy chains of antibody 5E8 having the amino acid sequences shown as amino acids 1-107 of SEQ ID NO: 6 and amino acids 1-118 SEQ ID NO: 8, respectively.

62. (Canceled) The method of claim 50, wherein parenteral administration includes subcutaneous, intravenous, intramuscular, rectal, vaginal and intraperitoneal administration.

63. (New) The method of claim 38, wherein the anti-human CD23 monoclonal antibody that is administered comprises the complementarity-determining regions CDR1, CDR2, and CDR3 of the light and heavy chains of antibody 6G5; wherein

CDR1, CDR2, and CDR3 of the light chain of antibody 6G5 are the polypeptides encoded by nucleotides 124-165, 211-231, and 328-357, respectively, of SEQ ID NO. 1; and

CDR1, CDR2, and CDR3 of the heavy chain of antibody 6G5 are the polypeptides encoded by nucleotides 148-165, 208-258, and 355-390, respectively, of SEQ ID NO. 3.

64. (New) The method of claim 38, wherein the anti-human CD23 monoclonal antibody that is administered comprises the complementarity-determining regions CDR1, CDR2, and CDR3 of the light and heavy chains of antibody 5E8; wherein

CDR1, CDR2, and CDR3 of the light chain of antibody 5E8 are the polypeptides encoded by nucleotides 136-168, 214-234, and 331-357, respectively, of SEQ ID NO. 5; and

CDR1, CDR2, and CDR3 of the heavy chain of antibody 5E8 are the polypeptides encoded by nucleotides 148-168, 211-261, and 358-378, respectively, of SEQ ID NO. 7.